Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Morote

Showing results (201-210 of 209) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 209 results.
Actas Urologicas Espanolas|March 30, 2004
[Inflammatory pseudotumor of the urinary bladder]J M Abascal Junquera, E Trilla Herrera, S Esquena Fernández, et al.
Actas Urologicas Espanolas|November 6, 2017
Cognitive function in patients on androgen suppression: A prospective, multicentric studyJ Morote, Á J Tabernero, J L Álvarez-Ossorio, et al.
Biomed Research International|February 5, 2015
Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell linesM Olivan, M Rigau, E Colás, et al.
Actas Urologicas Espanolas|April 13, 2004
[Von Hippel-Lindau disease: atypical presentation]J M Abascal Junquera, S Esquena Fernández, R Martos Calvo, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Actas Urologicas Espanolas|August 15, 2017
Systematic review of kidney transplantation functional predictorsE Miret Alomar, E Trilla Herrera, D Lorente Garcia, et al.
Archivos Espanoles De Urologia|June 1, 1996
[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]J Bellmunt Molins, A Ribas, J Albanell, et al.
British Journal of Cancer|June 27, 2013
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO studyA Alcaraz, R González-López, J Morote, et al.
British Journal of Cancer|June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyC de la Piedra, A Alcaraz, J Bellmunt, et al.
Pageof 21

Showing results (201-210 of 209) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
Actas Urologicas Espanolas|March 30, 2004
[Inflammatory pseudotumor of the urinary bladder]J M Abascal Junquera, E Trilla Herrera, S Esquena Fernández, et al.
Actas Urologicas Espanolas|November 6, 2017
Cognitive function in patients on androgen suppression: A prospective, multicentric studyJ Morote, Á J Tabernero, J L Álvarez-Ossorio, et al.
Biomed Research International|February 5, 2015
Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell linesM Olivan, M Rigau, E Colás, et al.
Actas Urologicas Espanolas|April 13, 2004
[Von Hippel-Lindau disease: atypical presentation]J M Abascal Junquera, S Esquena Fernández, R Martos Calvo, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Actas Urologicas Espanolas|August 15, 2017
Systematic review of kidney transplantation functional predictorsE Miret Alomar, E Trilla Herrera, D Lorente Garcia, et al.
Archivos Espanoles De Urologia|June 1, 1996
[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)]J Bellmunt Molins, A Ribas, J Albanell, et al.
British Journal of Cancer|June 27, 2013
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO studyA Alcaraz, R González-López, J Morote, et al.
British Journal of Cancer|June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyC de la Piedra, A Alcaraz, J Bellmunt, et al.
Pageof 21